News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cerus Corporation (CERS) Awarded $1.4 Million to Advance Development of Pathogen Inactivation for Red Blood Cells


9/23/2010 11:08:29 AM

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that it has received an additional $1.4 million from the U.S. Department of Defense to support advanced development of the company’s pathogen inactivation technology for red blood cells. The INTERCEPT red blood cell system is a pathogen inactivation product Cerus is developing to prevent the transmission of infectious diseases through red blood cell transfusions.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES